At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
In Vivo Pharmacology Associate Scientist (non-PhD)
We are seeking an In Vivo Pharmacology Associate Scientist to join the Oncology Discovery Pharmacology and In Vivo Biology group within the Mechanisms of Cancer Resistance (MoCR) organization at Bristol-Myers Squibb located in Cambridge, MA.
The qualified candidate is a highly motivated, interactive, and creative scientist who will conduct experiments utilizing tumor xenograft and genetically engineered mouse models to advance oncology discovery programs into the clinic. The successful candidate will demonstrate clear and professional communication, effectively collaborate with colleagues across a highly matrixed environment, and is capable of executing, analyzing and presenting scientific results.
Qualifications
* A B.S. with a minimum combined 2 years relevant Oncology industry and/or comparable academic experience leveraging in vivo rodent models to explore cancer biology and enable drug discovery is required.
* Required in vivo skills include: rodent handling, rodent dosing (IV, IP, SC, and PO routes), tumor measurements by caliper, and blood/tissue/tumor collection.
* Advanced in vivo skills are a plus, including but not limited to surgical experience with rodents and animal imaging.
* Proficiency in utilizing data analysis and presentation software such as Graph Pad, Microsoft office etc. for data analysis and figure generation is required.
* Attention to detail with excellent organizational and record keeping skills is a requirement.
Responsibilities include:
* Independently conduct and analyze in vivo mouse or rat studies including, ATD/MTD, anti-tumor efficacy, body weights, and generation of samples from PK/PD studies.
* Contribute to the utilization of ELISAs (MSD), qPCR, or WB to monitor relevant biomarkers in harvested tissues
* Accurately maintain proper scientific documentation of experiments and associated data in an electronic lab notebook.
* Effectively communicate and present summaries of research results to team members.
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Our company is committed to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace adjustments and ongoing support in their roles. Applicants can request an approval of accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or any part of the recruitment process direct your inquiries to adastaffingsupport@bms.com. Visit careers.bms.com/eeo-accessibility to access our complete Equal Employment Opportunity statement.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.